Loading
A pill that switches off the leukaemia's engine plus an immunotherapy that mops up survivors, with no chemotherapy.
A BCR::ABL1 tyrosine kinase inhibitor, ponatinib or dasatinib, combined with the CD19 bispecific blinatumomab offers chemotherapy-free treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia. The TKI collapses the Ph-positive clone quickly, and blinatumomab then clears residual disease at the MRD level, including subclones with kinase mutations, because its CD19 mechanism is independent of the kinase. The D-ALBA (GIMEMA LAL2116) trial with dasatinib and the MD Anderson series with ponatinib achieved molecular remission in most adults with far less toxicity than hyper-CVAD. The evidence is phase 2, and randomised comparisons against chemotherapy-containing regimens such as GIMEMA ALL2820 are under way; PhALLCON is the other linked trial.
Shares D-ALBA (GIMEMA LAL2116), Ph-positive ALL, Ponatinib, Dasatinib.
Shares Ponatinib, Chronic myeloid leukaemia, accelerated and blast phase, Dasatinib, Acute lymphoblastic leukaemia.
Shares Ponatinib, Chronic myeloid leukaemia, accelerated and blast phase, Dasatinib, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL).
Shares Ponatinib, Chronic myeloid leukaemia, accelerated and blast phase, Dasatinib, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL).
Shares Ponatinib, Chronic myeloid leukaemia, accelerated and blast phase, Acute lymphoblastic leukaemia.
Shares Ponatinib, Chronic myeloid leukaemia, accelerated and blast phase, Dasatinib, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL).
Shares Ponatinib, Chronic myeloid leukaemia, accelerated and blast phase.
Shares Dasatinib, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL).